Charette v. Wexford Health Sources Inc.

CourtDistrict Court, D. Maryland
DecidedMarch 23, 2021
Docket1:19-cv-00033
StatusUnknown

This text of Charette v. Wexford Health Sources Inc. (Charette v. Wexford Health Sources Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Charette v. Wexford Health Sources Inc., (D. Md. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

ANGELA CHARETTE, as personal * representative of THE ESTATE OF * MICHAEL MILLER * * v. * Civil Action No. CCB-19-0033 * WEXFORD HEALTH SOURCES, * INC., et al. * * ***** MEMORANDUM This is a medical malpractice and civil rights action concerning the alleged mistreatment of Michael Miller’s various medical conditions while he was incarcerated in state prison. The complaint was originally brought by Miller in January 2019. Following Miller’s death in August 2019, Angela Charette, the personal representative of Miller’s estate, was substituted as the plaintiff. The operative complaint alleges that the defendants, Wexford Health Sources, Inc. (“Wexford”) and various medical professionals it employed,1 treated Miller’s Hepatitis B, Hepatitis C, liver disease, and other ailments in a manner that fell below the standard of care and was constitutionally deficient. The defendants have filed three separate motions to dismiss some, but not all, of the claims against them. (See ECF 57, 58, 61). Each motion is now fully briefed and no oral argument is necessary. See Local Rule 105(6). For the reasons discussed herein, the motion to dismiss (ECF 61) will be granted and the other two motions (ECF 57, 58) will be granted in part and denied in part.

1 The court will refer to the employees named in this action collectively as the “medical defendants.” FACTS AND PROCEDURAL HISTORY According to the complaint, on Thanksgiving Day in 2016, Michael Miller was found eating tile off the floor of his cell at Jessup Correctional Institute (“JCI”). (ECF 56, Second Am. Compl. (“SAC”) ¶ 5). This followed numerous bouts of internal bleeding related to his untreated

hepatitis infection, which caused him to vomit and defecate blood and left him with a bacterial infection and a spinal abscess. (Id. ¶ 4). How Miller’s condition deteriorated to this point implicates the somewhat complicated history of the medical care he received over the six years prior to that Thanksgiving Day while he was incarcerated in the custody of the Maryland Department of Public Safety and Correctional Services (“DPSCS”). (Id. ¶¶ 1, 12). At the times relevant to this complaint, DPSCS contracted with Wexford to provide health care to its inmates. (Id. ¶¶ 13–15). Wexford in turn employed all of the other named defendants, including: Bolaji Onabajo, MD; Zowie Barnes, MD; Gedion Atnafu, MD; Ayoku Oketunji, MD; Robert Giangrandi, PA; Priscilla Momoh, PA; Bernard Alenda, CFNP; Jennifer Pope, CFNP; Wondaye Deressa, CFNP; Titilayo Otunuga, CFNP; Keshaun Temesgen, MD; Melaku Ayalew,

MD; and Kenneth Lee, MD. (Id. ¶¶ 16–29). In 2010, while at JCI, Miller tested positive for Hepatitis B (“HBV”) and Hepatitis C (“HCV”). (Id. ¶ 38). Both HBV and HCV are “serious medical conditions” that “attack the proper functioning of the liver.” (Id. ¶ 31). If left untreated, HBV and HCV will cause cirrhosis, “an advanced stage of liver malfunction” characterized by scarring which prevents the liver from properly filtering toxins in the blood and which presents “severe risks of serious harm and death.” (Id.). Prescription anti-viral drugs have been available to treat HBV and HCV since 2012 and 2013, respectively. (Id. ¶¶ 35–36). These drugs help to prevent the onset of cirrhosis, and, once it has presented, they help slow its progression. (Id. ¶ 35). The standard of care for treating HBV and HCV involves testing individuals suspected to have either infection, monitoring both the progress of the infection and the progression of the patient’s liver decompensation, and treating the patient with some combination of anti-viral medication. (Id. ¶¶ 31, 37). One symptom associated with severe cirrhosis is esophageal varices, which is “swollen or

ruptured veins near the esophagus and upper gastrointestinal tract.” (Id. ¶ 32). Esophageal varices can result in internal bleeding and poses a substantial risk of serious bodily harm. (Id. ¶ 33). The standard of care for treating esophageal varices is to perform banding ligation—the placement of miniscule rubber bands around the ruptured varices by endoscopy—and to refer the patient to a liver specialist for follow-up endoscopies to assess healing and to determine whether there are missing bands that need to be replaced. (Id. ¶¶ 33–34). When Miller first tested positive for HBV and HCV in 2010, he was given an HBV booster vaccination but he was not treated for HCV at that time. (Id. ¶ 38). Two years later, when Wexford assumed responsibility for his care, he again tested positive for HBV and HCV, though he alleges those test results were not shared with him. (Id. ¶¶ 39, 187). Miller’s HBV and HCV tests revealed

a low viral load count, indicating that his conditions were chronic rather than acute. (Id. ¶ 39). Chronic HBV is “more dangerous” than the more-common acute HBV, and typically requires prescription drug treatment. (Id. ¶ 40). Between 2013 and 2015, Miller had recurring episodes of gastrointestinal bleeding and exhibited symptoms of cirrhosis. (Id. ¶ 43). During this time, Miller had been transferred from JCI to a correctional facility in New Mexico. He was transferred back to JCI in August 2015, where he remained until his release from custody on March 23, 2017. (Id. ¶¶ 43, 45, 106). Even though Miller was in custody in New Mexico during this period of time, Wexford remained responsible for reviewing and approving his medical care. (Id. ¶¶ 43). Wexford approved one visit to an outside specialist to monitor Miller’s esophageal varices during this time period. (Id. ¶ 44). Charette alleges that Wexford maintains a policy and practice of interpreting “guidelines for treatment of HBV to indicate treatment only in the presence of detectable viral loads, despite

the fact that this is not the sole indicator for treatment.” (Id. ¶ 167). Between October 2015 and March 2016, the medical defendants “indicated in writing” that Miller was restricted from visiting the emergency room and instructed that he was to be monitored for active bleeding. (Id. ¶ 139). Charette alleges that Wexford supervisors and individuals with policymaking authority instructed the medical defendants not to refer Miller for follow-up treatment with an outside specialist. (Id. ¶ 140). Even after some of Wexford’s medical providers requested referrals, Oketunji, Temesgen, and Lee failed to provide Miller with treatment for HBV or HCV. (Id. ¶ 146). The defendants were aware that Miller had recurring ruptured esophageal varices, as indicated by his “repeated episodes of vomiting and defecating blood, abnormal fevers, and changes in mental state,” and yet they denied him medical care and refused to report his condition

or refer him for outside treatment. (Id. ¶¶ 181–82). As a result, he experienced pain and suffering and severe emotional distress due to his “multiple emergency procedures to correct life-threatening episodes of ruptured esophageal varices.” (Id. ¶¶ 178, 183). Wexford had notice of a “widespread practice wherein the company and its employees failed to keep records that could reliably track patient medical history.” (Id. ¶ 149). Wexford’s training and supervision of employees “was inadequate to alert its medical providers as to how accurate documentation could be maintained and retrieved within Wexford’s systems.” (Id. ¶ 165). From October 2015 to May 2016, Wexford’s deficient practices caused “Miller’s history of HBV infection” to “all but disappear[]” from their records. (Id. ¶ 154). And Ayalew’s May 2016 request for a referral was never submitted for approval. (Id. ¶ 155). Charette alleges that Wexford’s failure to maintain reliable records caused Miller to receive chronic care only for the HCV infection and not the HBV infection. (Id. ¶¶ 158, 163). Charette also alleges that this inadequate system for maintaining medical records served to

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Ex Parte Virginia
100 U.S. 339 (Supreme Court, 1880)
Jackson v. Metropolitan Edison Co.
419 U.S. 345 (Supreme Court, 1974)
Bounds v. Smith
430 U.S. 817 (Supreme Court, 1977)
Monell v. New York City Dept. of Social Servs.
436 U.S. 658 (Supreme Court, 1978)
City of Oklahoma v. Tuttle
471 U.S. 808 (Supreme Court, 1985)
Pembaur v. City of Cincinnati
475 U.S. 469 (Supreme Court, 1986)
West v. Atkins
487 U.S. 42 (Supreme Court, 1988)
Owens v. Okure
488 U.S. 235 (Supreme Court, 1989)
Lewis v. Casey
518 U.S. 343 (Supreme Court, 1996)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
United States v. Kathleen Tobin
155 F.3d 636 (Third Circuit, 1998)
Riddick v. School Board Of The City Of Portsmouth
238 F.3d 518 (Fourth Circuit, 2000)
Wag More Dogs, Ltd. Liability Corp. v. Cozart
680 F.3d 359 (Fourth Circuit, 2012)
Bizzie Walters v. Todd McMahen
684 F.3d 435 (Fourth Circuit, 2012)
Goodman v. Praxair, Inc.
494 F.3d 458 (Fourth Circuit, 2007)
Dua v. Comcast Cable of Maryland, Inc.
805 A.2d 1061 (Court of Appeals of Maryland, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
Charette v. Wexford Health Sources Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/charette-v-wexford-health-sources-inc-mdd-2021.